Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?|
|Citation:||Internal Medicine Journal, 2012; 42(4):450-455|
|Publisher:||Blackwell Publishing Asia|
|R.J. Bird, M. Kenealy, C. Forsyth, J. Wellwood, M.F. Leahy, J.F. Seymour and L.B. To|
|Abstract:||Despite the absence of a robust evidence base, there is growing consensus that effective treatment of iron overload leads to decreased morbidity and premature mortality in patients with good prognosis myelodysplastic syndromes (MDSs). Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis MDS, who might also benefit from iron chelation. This article proposes assessment of patients with MDS and related bone marrow failure syndromes to determine suitability for iron chelation. Iron chelation therapy options and monitoring are discussed.|
|Keywords:||Myeodysplasia; iron; chelation|
|Rights:||© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians|
|Appears in Collections:||Medical Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.